✦ LIBER ✦

PCN100 A Cost–Utility Analysis of Degarelix in the Treatment of Advanced Hormone-Dependent Prostate Cancer in Scotland

✍ Scribed by Fisher, D.; Brereton, N.J.; Kildegaard nielsen, S.; Tate, E.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness analysis of degarelix

✍ Lanting Lu; Jaime Peters; Chris Roome; Ken Stein 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 601 KB

Re: Cost-Effectiveness Analysis of Degar

✍ Penson, David F. 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 94 KB

PCN70 The Cost Effectiveness of Degareli

✍ D. Lee; D. Gladwell; S.K. Nielsen; E. Tate; N.J. Brereton 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN122 COST-EFFECTIVENESS ANALYSIS OF HO

✍ S Iannazzo; L Pradelli; M Perachino 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PCN47 COST-UTILITY ANALYSIS OF OXALIPLAT

✍ N Muszbek; R Odhiambo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN8 COST-EFFECTIVENESS ANALYSIS OF LHRH

✍ M Iskedjian; M Hemels; N Iscoe; N Fleshner; T Einarson 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB